Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.

@article{Kohlmann2015SerologicalEO,
  title={Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.},
  author={Rebekka Kohlmann and Anke Salmen and Andrew Chan and Cornelius Knabbe and J{\"u}rgen Diekmann and Norbert H Brockmeyer and Adriane Skaletz-Rorowski and Claudia Michalik and Ralf Gold and Klaus {\"U}berla},
  journal={Multiple sclerosis},
  year={2015},
  volume={21 14},
  pages={1823-32}
}
BACKGROUND Serious adverse drug reactions of disease-modifying drugs in multiple sclerosis (MS) therapy may include enhanced susceptibility to reactivation of neurotropic herpes viruses like varicella-zoster virus (VZV) and the John Cunningham (JC) polyomavirus. OBJECTIVE Because symptomatic reactivation of these viruses are rare events, we determined the incidence of rises in anti-VZV IgG antibody levels as a potential marker for enhanced susceptibility to subclinical and symptomatic… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab

Neurology(R) neuroimmunology & neuroinflammation • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2013

PML-Inzidenz unter Tysabri® nach Marktzulassung. Patientenregister, www.tysabri.de

Biogen Idec
2013

Similar Papers

Loading similar papers…